Picard Medical’s Next-Gen Emperor TAH Demonstrates Stable Support in 3 Preclinical Implants
PMI•Picard Medical completed three acute in vivo implant studies of its next-gen Emperor Total Artificial Heart, demonstrating stable full circulatory support with its independent dual-motor ventricular design and no device-related failures. The successful preclinical results advance development toward a fully implantable artificial heart system supporting future commercialization potential.
1. Preclinical Implant Study Results
Picard Medical completed three acute in vivo implant procedures of the next-generation Emperor TAH at Banner University Medical Center in Tucson, demonstrating stable full circulatory support with observations consistent with physiologic autoregulatory behavior. The independent dual-motor ventricular system enabled side-specific control of systemic and pulmonary circulation, and no device-related intraoperative failures were observed across all study procedures.
2. Emperor TAH Design and Development Outlook
The Emperor TAH platform builds on the blood-contacting architecture and clinical experience of the SynCardia Total Artificial Heart while advancing patient mobility toward a fully implantable system that does not require external pneumatic drivers. The successful preclinical data support ongoing system optimization and translational studies as Picard Medical advances development of a next-generation artificial heart device.
